p3xFLAG CMV14 / BRAF-D594G
(Plasmid
#131719)
-
PurposeMammalian Expression of Flag tagged BRAF
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 131719 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonep3xFLAG-CMV-14
-
Backbone manufacturerSigma-Aldrich
- Backbone size w/o insert (bp) 6310
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameBRAF
-
Alt nameB-RAF
-
Alt nameENSG00000157764
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2301
-
MutationD594G
-
Entrez GeneBRAF (a.k.a. B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1)
- Promoter CMV
-
Tag
/ Fusion Protein
- 3xFLAG (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site Unknown (unknown if destroyed)
- 3′ cloning site Unknown (unknown if destroyed)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Please also see https://www.ncbi.nlm.nih.gov/pubmed/29662630.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
p3xFLAG CMV14 / BRAF-D594G was a gift from Jacques De Grève (Addgene plasmid # 131719 ; http://n2t.net/addgene:131719 ; RRID:Addgene_131719) -
For your References section:
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, De Greve J. Oncotarget. 2016 Aug 26;8(36):60094-60108. doi: 10.18632/oncotarget.11635. eCollection 2017 Sep 1. 10.18632/oncotarget.11635 PubMed 28947956